Here we report the results of extensive genomic interrogation of a BRCA2-mutant prostate cancer patient with acquired resistance to PARPi combination therapy mediated by multiple BRCA2 reversion mutations. The gene discussed is BRCA2; the disease is prostate carcinoma.